Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [1]. TNBC accounts for approximately 15-20% of all breast cancer cases [2]. Due to the absence of these receptors, targeted therapies commonly used for other types of breast cancer are not effective in TNBC treatment, making it a challenging disease to manage [2].

However, there have been recent developments in the understanding and treatment of TNBC. Researchers have been exploring various approaches to improve outcomes for patients with TNBC, including novel drug targets and combination therapies.

One recent study published in the Journal of Hematology & Oncology investigated the role of the immune system in TNBC and identified potential immunotherapeutic targets [2]. The study highlighted the importance of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, in enhancing the immune response against TNBC cells. The researchers also discussed the potential of combining immunotherapies with chemotherapy or targeted therapies to achieve better treatment outcomes [2].

Another study published in Molecular Cancer explored the role of a protein called MTH1 in TNBC [3]. The researchers found that inhibiting MTH1 could potentially enhance the efficacy of chemotherapy drugs used in TNBC treatment. The study suggested that targeting MTH1 could be a promising strategy for improving the response to chemotherapy in TNBC patients [3].

In addition to these studies, it is important to note that ongoing research and clinical trials are continuously evaluating new treatment options for TNBC. These trials aim to identify and test novel drugs, targeted therapies, and combination treatments to improve patient outcomes [1].

In conclusion, recent developments in the understanding and treatment of TNBC have focused on exploring immunotherapeutic targets, such as immune checkpoint inhibitors, as well as investigating the role of specific proteins, like MTH1, in enhancing the efficacy of chemotherapy. Ongoing research and clinical trials are essential in advancing the field and providing new treatment options for patients with TNBC.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/TRIPLE
[2] https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01497-3
[3] https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01183-9